Sugi Predict

Sugi Predict / Compounds / SCHEMBL4420626

SCHEMBL4420626

SCHEMBL4420626

CC(C)C[C@@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)OC1CCCC1)[C@H](CC=Cc1ccccc1)C(=O)NO

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 16/20 0.55
▸ MMP3 P08254 14/20 0.55
▸ MMP7 P09237 13/20 0.55
▸ MMP1 P03956 11/20 0.54
▸ MMP9 P14780 3/20 0.54
▸ MMP8 P22894 2/20 0.54
▸ ADAM17 P78536 2/20 0.54
▸ MMP12 P39900 1/20 0.54
▸ MMP13 P45452 1/20 0.54
▸ MMP14 P50281 1/20 0.54
▸ ANPEP P15144 2/20 0.54
▸ LTA4H P09960 1/20 0.54
▸ LAP3 P28838 1/20 0.54
▸ NPEPPS P55786 1/20 0.54
▸ ERAP2 Q6P179 1/20 0.54
▸ ERAP1 Q9NZ08 1/20 0.54
▸ FCER2 P06734 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6801571 0.94 MMP2 (0.50) MMP2MMP3MMP7MMP1MMP9
SCHEMBL13696746 0.90 MMP2 (0.70) MMP2MMP3MMP7MMP1MMP9
SCHEMBL4422495 0.90 MMP2 (0.70) MMP2MMP3MMP7MMP1MMP9
SCHEMBL7883057 0.90 MMP2 (0.70) MMP2MMP3MMP7MMP1MMP9
SCHEMBL7883062 0.90 MMP2 (0.70) MMP2MMP3MMP7MMP1MMP9
SCHEMBL4422794 0.89 MMP2 (0.69) MMP2MMP3MMP7MMP1MMP9
SCHEMBL7654835 0.82 MMP2 (0.59) MMP2MMP3MMP7MMP1MMP9
SCHEMBL4431005 0.81 MMP2 (0.66) MMP2MMP3MMP7MMP1MMP9
SCHEMBL4425948 0.80 MMP2 (0.64) MMP2MMP3MMP7MMP1MMP9
SCHEMBL6804722 0.79 MMP2 (0.65) MMP2MMP3MMP7MMP1MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4238334-B2 — — 2009-03-18 — — JP claimed
US-6790834-B1 Cytostatic agents BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) 2004-09-14 — — US claimed
EP-0925278-B1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARM (GB) 2002-07-17 — — EP claimed
JP-2001500149-A — — 2001-01-09 — — JP claimed
EP-0925278-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-06-30 — — EP claimed
WO-1998011063-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-03-19 — — WO claimed
US-20220226304-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase ALKAHEST, INC. 2022-07-21 — — US disclosed
US-11344542-B2 Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase ALKAHEST, INC. (US) 2022-05-31 — — US disclosed
US-20200368220-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase ALKAHEST, INC. 2020-11-26 — — US disclosed
US-20190350917-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase ALKAHEST, INC. 2019-11-21 — — US disclosed
US-6790834-B1 Cytostatic agents BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) 2004-09-14 — — US disclosed
US-6462023-B1 SUCH AS 2-HYDROXY-HYDROXYCARBAMOYL-METHYL)-4-METHYL-PENTANOYLAMINE)-2-PHENYL -ETHANOIC ACID CYCLOPENTYL ESTER; INHIBITING HYPERPROLIFERATIVE TUMOURGENIC CELLS SUCH AS MELANOMA AND/OR LYMPHOMA CELLS BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) 2002-10-08 — — US disclosed
EP-0925278-B1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARM (GB) 2002-07-17 — — EP disclosed
EP-1063984-A1 INFLAMMATORY CELL INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2001-01-03 — — EP disclosed
US-6169075-B1 ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2001-01-02 — — US disclosed
EP-1052986-A1 ANTI-INFLAMMATORY AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 2000-11-22 — — EP disclosed
WO-1999044602-A1 INFLAMMATORY CELL INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-09-10 — — WO disclosed
WO-1999040910-A1 ANTI-INFLAMMATORY AGENTS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-08-19 — — WO disclosed
EP-0925278-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1999-06-30 — — EP disclosed
WO-1998011063-A1 CYTOSTATIC HYDROXAMIC ACID DERIVATIVES BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1998-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11344542-B2 Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase LTA4H, LTB4R, LTC4S MMP2 507/4885MMP3 455/4885MMP7 814/4885
US-20190350917-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase LTA4H, LTB4R, LTC4S MMP2 507/4885MMP3 455/4885MMP7 814/4885
US-20220226304-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase LTA4H, LTB4R, LTC4S MMP2 507/4885MMP3 455/4885MMP7 814/4885
US-20200368220-A1 Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase LTA4H, LTB4R, LTC4S MMP2 507/4885MMP3 455/4885MMP7 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.